{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021390739808384.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s10147-023-02382-2"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1007/s10147-023-02382-2.pdf"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/article/10.1007/s10147-023-02382-2/fulltext.html"}},{"identifier":{"@type":"PMID","@value":"37453935"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2025021444"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022"}],"description":[{"notation":[{"@value":"Cisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance)  45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (tumor lysis syndrome). Preventative rasburicase is recommended in high-risk cases of TLS. Thrombotic microangiopathy could be triggered by anticancer drugs and there is no evidence of efficacy of plasma exchange therapy. When proteinuria occurs during treatment with anti-angiogenic agents or multi-kinase inhibitors, dose reductions or interruptions based on grading should be considered. Grade 3 proteinuria and renal dysfunction require urgent intervention, including drug interruption or withdrawal, and referral to a nephrologist should be considered. The first-line drugs used for blood pressure elevation due to anti-angiogenic agents are ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers). The protein binding of drugs and their pharmacokinetics are considerably altered in patients with hypoalbuminemia. The clearance of rituximab is increased in patients with proteinuria, and the correlation with urinary IgG suggests similar pharmacokinetic changes when using other antibody drugs. AIN (acute interstitial nephritis) is the most common cause of ICI (immune checkpoint inhibitor)-related kidney injury that is often treated with steroids. The need for renal biopsy in patients with kidney injury that occurs during treatment with ICI remains controversial."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021390739808522","@type":"Researcher","foaf:name":[{"@value":"Yuichi Ando"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808390","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Nishiyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276166153728","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70373214"},{"@type":"NRID","@value":"1000070373214"},{"@type":"NRID","@value":"9000413509580"},{"@type":"NRID","@value":"9000389942169"},{"@type":"NRID","@value":"9000398029910"},{"@type":"NRID","@value":"9000414368216"},{"@type":"NRID","@value":"9000000381438"},{"@type":"NRID","@value":"9000379073229"},{"@type":"NRID","@value":"9000317563888"},{"@type":"NRID","@value":"9000412282480"},{"@type":"NRID","@value":"9000391520119"},{"@type":"NRID","@value":"9000399221974"},{"@type":"NRID","@value":"9000398609872"},{"@type":"NRID","@value":"9000399243614"},{"@type":"NRID","@value":"9000242742973"},{"@type":"NRID","@value":"9000399801466"},{"@type":"NRID","@value":"9000387472532"},{"@type":"NRID","@value":"9000389000068"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/hidekishimodaira"}],"foaf:name":[{"@value":"Hideki Shimodaira"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808644","@type":"Researcher","foaf:name":[{"@value":"Nao Takano"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808672","@type":"Researcher","foaf:name":[{"@value":"Emiko Sakaida"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808402","@type":"Researcher","foaf:name":[{"@value":"Koji Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808554","@type":"Researcher","foaf:name":[{"@value":"Koki Nakanishi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808392","@type":"Researcher","foaf:name":[{"@value":"Hideki Sakai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808547","@type":"Researcher","foaf:name":[{"@value":"Shokichi Tsukamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808515","@type":"Researcher","foaf:name":[{"@value":"Keigo Komine"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801188471808","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"60432259"},{"@type":"NRID","@value":"1000060432259"},{"@type":"NRID","@value":"9000413509572"},{"@type":"NRID","@value":"9000412352283"},{"@type":"NRID","@value":"9000261672821"},{"@type":"NRID","@value":"9000256094264"},{"@type":"NRID","@value":"9000001774784"},{"@type":"NRID","@value":"9000405616984"},{"@type":"NRID","@value":"9000413470899"},{"@type":"NRID","@value":"9000020869968"},{"@type":"NRID","@value":"9000259311221"},{"@type":"NRID","@value":"9000020305258"},{"@type":"NRID","@value":"9000263059768"},{"@type":"NRID","@value":"9000242444455"},{"@type":"NRID","@value":"9000303160818"},{"@type":"NRID","@value":"9000279910821"},{"@type":"NRID","@value":"9000248221490"},{"@type":"NRID","@value":"9000333086616"},{"@type":"NRID","@value":"9000369747550"},{"@type":"NRID","@value":"9000415213495"},{"@type":"NRID","@value":"9000305640647"},{"@type":"NRID","@value":"9000018557806"},{"@type":"NRID","@value":"9000020611303"},{"@type":"NRID","@value":"9000242071506"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/nephrol"}],"foaf:name":[{"@value":"Yoshinari Yasuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808409","@type":"Researcher","foaf:name":[{"@value":"Taigo Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808527","@type":"Researcher","foaf:name":[{"@value":"Yutaka Fujiwara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808770","@type":"Researcher","foaf:name":[{"@value":"Takafumi Koyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808557","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Kitamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276158436352","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00393356"},{"@type":"NRID","@value":"1000000393356"},{"@type":"NRID","@value":"9000326666132"},{"@type":"NRID","@value":"9000312259385"},{"@type":"NRID","@value":"9000003913148"},{"@type":"NRID","@value":"9000411517229"},{"@type":"NRID","@value":"9000002025983"},{"@type":"NRID","@value":"9000014666625"},{"@type":"NRID","@value":"9000312259401"},{"@type":"NRID","@value":"9000347361670"},{"@type":"NRID","@value":"9000312259414"},{"@type":"NRID","@value":"9000415050287"},{"@type":"NRID","@value":"9000264550662"},{"@type":"NRID","@value":"9000415419252"},{"@type":"NRID","@value":"9000329440351"},{"@type":"NRID","@value":"9000414561313"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/ktakasea"}],"foaf:name":[{"@value":"Takashige Kuwabara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808546","@type":"Researcher","foaf:name":[{"@value":"Atsushi Yonezawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808548","@type":"Researcher","foaf:name":[{"@value":"Yuta Okumura"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808552","@type":"Researcher","foaf:name":[{"@value":"Kimikazu Yakushijin"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808648","@type":"Researcher","foaf:name":[{"@value":"Kazuki Nozawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808393","@type":"Researcher","foaf:name":[{"@value":"Hideaki Goto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808655","@type":"Researcher","foaf:name":[{"@value":"Takeshi Matsubara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808675","@type":"Researcher","foaf:name":[{"@value":"Junichi Hoshino"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021390739808549","@type":"Researcher","foaf:name":[{"@value":"Motoko Yanagita"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13419625"},{"@type":"EISSN","@value":"14377772"}],"prism:publicationName":[{"@value":"International Journal of Clinical Oncology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2023-07-16","prism:volume":"28","prism:number":"10","prism:startingPage":"1315","prism:endingPage":"1332"},"reviewed":"false","dc:rights":["https://www.springernature.com/gp/researchers/text-and-data-mining","https://www.springernature.com/gp/researchers/text-and-data-mining"],"url":[{"@id":"https://link.springer.com/content/pdf/10.1007/s10147-023-02382-2.pdf"},{"@id":"https://link.springer.com/article/10.1007/s10147-023-02382-2/fulltext.html"},{"@id":"https://search.jamas.or.jp/link/ui/2025021444"}],"createdAt":"2023-07-16","modifiedAt":"2023-09-29","project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782001208704","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"18K09270"},{"@type":"JGN","@value":"JP18K09270"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K09270/"}],"notation":[{"@language":"ja","@value":"BRCA1遺伝子ミスセンスバリアントのライブラリー作成とがんゲノム医療への応用"},{"@language":"en","@value":"Biological analyses of BRCA1 gene missense variants for application to cancer genome medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1040003825719401856","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"20H03575"},{"@type":"JGN","@value":"JP20H03575"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20H03575/"}],"notation":[{"@language":"ja","@value":"メタボローム解析を活用した腎血漿流量とより正確な糸球体濾過量推算式の開発"},{"@language":"en","@value":"Renal plasma flow (RPF) and accurate GFR equations utilizing metabolomics analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1040010457607600896","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22K08350"},{"@type":"JGN","@value":"JP22K08350"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K08350/"}],"notation":[{"@language":"ja","@value":"免疫チェックポイント阻害薬に関連した腎障害における三次リンパ節の機能解析"},{"@language":"en","@value":"Pathologic analysis of tertiary lymphoid tissue in acute interstitial nephritis associated with immune-checkpoint inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1040291932566434176","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22K08357"},{"@type":"JGN","@value":"JP22K08357"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K08357/"}],"notation":[{"@language":"ja","@value":"細胞性免疫による急性腎障害進展機序に果たすMRP8の役割"},{"@language":"en","@value":"Role of MRP8 in the mechanism of acute kidney injury through cell-mediated immunity"}]},{"@id":"https://cir.nii.ac.jp/crid/1040850857191829888","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"21K07248"},{"@type":"JGN","@value":"JP21K07248"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K07248/"}],"notation":[{"@language":"ja","@value":"CDKN2A遺伝子バリアントに対する機能評価法の確立とがんゲノム医療への応用"},{"@language":"en","@value":"Functional assay to estimate the significance of variants in CDKN2A gene detected in cancer genome testing"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050282812903673472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats"},{"@value":"Enhanced renal accumulation of CDDP via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1050845763182203520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin’s Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144240925056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Understanding and Managing Methotrexate Nephrotoxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145180269824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145190247552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146223247232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360016866462126592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017289999501568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ifosfamide-Induced Nephrotoxicity: Mechanism and Prevention"}]},{"@id":"https://cir.nii.ac.jp/crid/1360020998593487744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021393788028288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Utility of Routine Proteinuria Evaluation in Treatment Decisions of Patients Receiving Bevacizumab for Metastatic Solid Tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618590761600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cisplatin nephrotoxicity in children after continuous 72-h and 3×1-h infusions"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619909802624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620275707648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620885834368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiorenal complications of immune checkpoint inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620895066752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298341864426368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bevacizumab-induced hypertension: Clinical presentation and molecular understanding"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298343484821760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298345582390400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298759598549632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cumulative pemetrexed dose increases the risk of nephrotoxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302474811832448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866831239168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093947445376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094414669184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095124897792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095525999616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095630765056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095891538176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cisplatin and hypomagnesemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576120338404352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576217418072576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580240144154752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340707491328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references","isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344408749312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344432657280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344433503744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AA amyloidosis associated with pulmonary squamous cell carcinoma treated with chemoradiation and immune checkpoint inhibitor therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344433683328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346109012736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346109238784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tolerability of Highly Protein Bound Targeted Oral Oncolytic Drugs in Patients With Hypoalbuminemia: A Retrospective Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346109308416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AKI in Patients Receiving Immune Checkpoint Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657643581056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569296961408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Thrombotic Microangiopathy, Cancer, and Cancer Drugs"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857598000791552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A decade of immune-checkpoint inhibitors in cancer therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861295092864256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865816807241728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818712564224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818732479232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818732618752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immune checkpoint inhibitor–associated renal amyloid A amyloidosis: A case series and review of the literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818732634368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Managing Toxicities Associated With Antiangiogenic Biologic Agents in Combination With Chemotherapy for Metastatic Colorectal Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818732635904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ifosfamide, Fanconi's syndrome, and rickets."}]},{"@id":"https://cir.nii.ac.jp/crid/1360865820417341440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypoalbuminemia in children with cancer treated with chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865820417913216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865820418306304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045265403648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045351311104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045822015488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046024944256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046138900224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mechanisms of Cisplatin Nephrotoxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518608955264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521387000832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521414026368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994421815680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994609164800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994678660480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995598237696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-CTLA4 Antibody–Induced Lupus Nephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469086401664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469350065280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of hypertension in angiogenesis inhibitor-treated patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469662255744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469911088512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471004307968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471055620864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Vascular Complications of Cancer Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471402088320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943836453248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945414524672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419143526400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419282355328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420151091968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of Cancer in Membranous Nephropathy: A Systematic Review and Meta-Analysis of Observational Studies"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420837688320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420887914240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics of drugs in patients with the nephrotic syndrome."}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893677969536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893867294720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895594553344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896151966080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369397008640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"VEGF Inhibition and Renal Thrombotic Microangiopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369592420480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369895390720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371359744000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844553174528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844908970240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845118876416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845248541312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846054836608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319629990400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793266651776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793880494976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795228437632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795392045184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiovascular Complications of Cancer Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268708000512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269002732288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269360034816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269588692224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269670272128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270110419200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"True"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270699447296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotic Syndrome After Bevacizumab: Case Report and Literature Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270943766272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679851028224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1881428067885269376","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Faculty Opinions recommendation of Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study."}]},{"@id":"https://cir.nii.ac.jp/crid/2051433317034740480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Kidney biopsy guidebook 2020 in Japan"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s10147-023-02382-2"},{"@type":"KAKEN","@value":"PRODUCT-24983839"},{"@type":"KAKEN","@value":"PRODUCT-24927270"},{"@type":"KAKEN","@value":"PRODUCT-25135276"},{"@type":"KAKEN","@value":"PRODUCT-24927233"},{"@type":"KAKEN","@value":"PRODUCT-24886778"},{"@type":"OPENAIRE","@value":"doi_dedup___::9516ef29ae474bd5a2469e78ca56701f"},{"@type":"CROSSREF","@value":"10.1007/s10157-023-02415-0_references_DOI_DuQnqvKRFB3ECsw0VGvMP3DkZxl"},{"@type":"CROSSREF","@value":"10.1007/s10147-023-02372-4_references_DOI_DuQnqvKRFB3ECsw0VGvMP3DkZxl"},{"@type":"CROSSREF","@value":"10.1007/s10147-023-02377-z_references_DOI_DuQnqvKRFB3ECsw0VGvMP3DkZxl"}]}